James Buteau (@buteaujames) 's Twitter Profile
James Buteau

@buteaujames

PhD candidate, PSMA theranostics, nuclear medicine consultant, Peter Mac

ID: 1240406717722062849

calendar_today18-03-2020 22:36:37

600 Tweet

501 Followers

311 Following

ProsTIC (@pros_tic) 's Twitter Profile Photo

Our webinars are back! Join us in Unravelling PSMA Biology on April 23/24 with Michael Hofman, PCF Science, GU Cast | Urology podcast! and our special guest speakers: Misha Beltran, Louise Emmett, Edmond Kwan & Martin Pomper, MD PhD šŸ”¬ Live, interactive and FREEā€¼ļø Register now: link.prostic.org/webinar

Our webinars are back! Join us in Unravelling PSMA Biology on April 23/24 with <a href="/DrMHofman/">Michael Hofman</a>, <a href="/PCF_Science/">PCF Science</a>, <a href="/gu_onc/">GU Cast | Urology podcast!</a> and our special guest speakers: <a href="/mishabeltran/">Misha Beltran</a>, <a href="/drlouiseemmett/">Louise Emmett</a>, <a href="/EdmondMKwan/">Edmond Kwan</a> &amp; <a href="/radnucmp/">Martin Pomper, MD PhD</a> šŸ”¬ 
Live, interactive and FREEā€¼ļø 
Register now: link.prostic.org/webinar
Michael Hofman (@drmhofman) 's Twitter Profile Photo

We are seeking a clinical trial co-ordinator who wants to make a true impact... at Peter Mac Cancer Centre . you’ll lead the coordination of our ProsTIC clinical trials, building on more than a decade of global leadership in cutting-edge research. Why Join Us? ⦿ Global Recognition: We

We are seeking a clinical trial co-ordinator who wants to make a true impact... at <a href="/PeterMacCC/">Peter Mac Cancer Centre</a> . you’ll lead the coordination of our <a href="/pros_tic/">ProsTIC</a>  clinical trials, building on more than a decade of global leadership in cutting-edge research.

Why Join Us?
⦿ Global Recognition: We
Michael Hofman (@drmhofman) 's Twitter Profile Photo

ProsTIC is looking for an Administrative Officer Peter Mac Cancer Centre! You'll play a key role in managing admin tasks, grant applications, travel coordination, reimbursements, and keeping our social media active (website, LinkedIn , YouTube, X). You'll also help organize

<a href="/pros_tic/">ProsTIC</a> is looking for an Administrative Officer <a href="/PeterMacCC/">Peter Mac Cancer Centre</a>!

You'll play a key role in managing admin tasks, grant applications, travel coordination, reimbursements, and keeping our social media active (website, <a href="/LinkedIn/">LinkedIn</a> , <a href="/YouTube/">YouTube</a>, <a href="/X/">X</a>).

You'll also help organize
Michael Hofman (@drmhofman) 's Twitter Profile Photo

I hope the 2025 Eric Susman Prize inspires many many people to explore a career in nuclear medicine—a fascinating and rapidly evolving internal medicine specialty of the The Royal Australasian College of Physicians, still relatively under the radar. There's never been a more exciting time to be part of this field.

Michael Hofman (@drmhofman) 's Twitter Profile Photo

New Frontiers in PSMA Radioligand Therapy Is this the "hottest" session at ASCO #ASCO25 ?? ā–  VIOLET: First-in-human trial of Terbium-161 ā–  BULLSEYE: Lu-PSMA in oligo-metastatic disease ā–  ENZA-p: Biomarkers ProsTIC PCF Science

New Frontiers in PSMA Radioligand Therapy

Is this the "hottest" session at <a href="/ASCO/">ASCO</a> #ASCO25  ??

ā–  VIOLET: First-in-human trial of Terbium-161
ā–  BULLSEYE: Lu-PSMA in oligo-metastatic disease
ā–  ENZA-p: Biomarkers

<a href="/pros_tic/">ProsTIC</a> <a href="/PCF_Science/">PCF Science</a>
Michael Hofman (@drmhofman) 's Twitter Profile Photo

Incredible prognostic power of PSMA PET from the updated PROMISE large international registry (PPP2): 3 and 5-yr survival data. Superior to NCCN risk score. Data across initial stage, biochemical recurrence, "non-metastatic" castration-resistant, mSPC, MCRPC !! Just out in

Incredible prognostic power of PSMA PET from the updated PROMISE large international registry (PPP2): 3 and 5-yr survival data. Superior to NCCN risk score. 

Data across initial stage, biochemical recurrence, "non-metastatic" castration-resistant, mSPC, MCRPC !!

Just out in
JNM (@journalofnucmed) 's Twitter Profile Photo

⁶⁸Ga-NeoB PET/CT has diagnostic potential in the staging of ER/PR-positive and HER2-negative breast cancer. Learn more: ow.ly/NJVA50VuLRT #NuclearMedicine #BreastCancer #PETscan Zahra Sabahi Louise Emmett Cindy Mak

⁶⁸Ga-NeoB PET/CT has diagnostic potential in the staging of ER/PR-positive and HER2-negative breast cancer. Learn more: ow.ly/NJVA50VuLRT 

#NuclearMedicine #BreastCancer #PETscan <a href="/Zahra_S_M_/">Zahra Sabahi</a> <a href="/drlouiseemmett/">Louise Emmett</a> <a href="/DrMakSurgeon/">Cindy Mak</a>
Michael Hofman (@drmhofman) 's Twitter Profile Photo

Stunning research from Edmond Kwan on ctDNA in theranostics: 🧬Low ctDNA predicts better response with ¹⁷⁷Lu-PSMA-617 vs. cabazitaxel chemotherapy āš ļøPTEN alterations linked to worse outcomes on cabazitaxel 🧪ATM defects tied to favorable PSMA-617 results 🩻PET quantitative

Stunning research from <a href="/EdmondMKwan/">Edmond Kwan</a> on ctDNA in theranostics:
🧬Low ctDNA predicts better response with ¹⁷⁷Lu-PSMA-617 vs. cabazitaxel chemotherapy
āš ļøPTEN alterations linked to worse outcomes on cabazitaxel
🧪ATM defects tied to favorable PSMA-617 results
🩻PET quantitative
Michael Hofman (@drmhofman) 's Twitter Profile Photo

Sneak previewšŸ‘‡ Don't miss it ASCO #ASCO25 Theranostics has revolutanized Prostate Cancer care with PSMA… …the next target is now ā€œclearā€ Sat May 31 8:00 AM Hall D2 State of the Science: Advancing Frontiers — Novel Diagnostics and Therapeutics in Renal Cell Carcinoma and

Edmond Kwan (@edmondmkwan) 's Twitter Profile Photo

On the eve of #ASCO25, I am delighted to share results from the correlative analyses of the ANZUP phase II TheraP study, now published in Nature Medicine. Massive effort supported by dedicated co-investigators, coordinators, patients & families from 11 study sites across

On the eve of #ASCO25, I am delighted to share results from the correlative analyses of the <a href="/ANZUPtrials/">ANZUP</a> phase II TheraP study, now published in <a href="/NatureMedicine/">Nature Medicine</a>. Massive effort supported by dedicated co-investigators, coordinators, patients &amp; families from 11 study sites across
Michael Hofman (@drmhofman) 's Twitter Profile Photo

Getting ready for ASCO #ASCO25? āœˆļøšŸ”¬ There’s lots of theranostics … including a dedicated session for prostate cancer. Don’t miss these! šŸ‘€

Getting ready for <a href="/ASCO/">ASCO</a> #ASCO25? āœˆļøšŸ”¬

There’s lots of theranostics … including a dedicated session for prostate cancer. 

Don’t miss these! šŸ‘€
Michael Hofman (@drmhofman) 's Twitter Profile Photo

Don't miss the first-in-human VIOLET study being presented #ASCO25 ASCO Monday June 2 3:00 PM New Frontiers in Prostate-Specific Membrane Antigen Radioligand Therapy (awesome research being presented in this session - don't miss the other talks) In press The Lancet Oncology

Michael Hofman (@drmhofman) 's Twitter Profile Photo

#VIOLET Study of Terbium-161 (Tb-161) Beta/Auger therapy ASCO #ASCO25 First prospective trial of Terbium-161 in any tumour type 🟣 30 patient trial in prostate cancer. No dose limiting toxicities at highest level of radioactivity (7.4 GBq) 🟣 Very few side effects: 1 grade 3

#VIOLET Study of Terbium-161 (Tb-161) Beta/Auger therapy <a href="/ASCO/">ASCO</a> #ASCO25

First prospective trial of Terbium-161 in any tumour type
🟣 30 patient trial in prostate cancer. No dose limiting toxicities at highest level of radioactivity (7.4 GBq)
🟣 Very few side effects: 1 grade 3
Advanced Prostate Cancer Consensus Conference (@apccc_lugano) 's Twitter Profile Photo

First-in-human results of terbium-161[161Tb]Tb-PSMA-I&T radioligand treatment in patients with metastatic castration-resistant prostate cancer (VIOLET) Presented at #ASCO25 meetings.asco.org/abstracts-pres… In this phase I/II trial, the novel radioligand therapy [¹⁶¹Tb]Tb-PSMA-I&T

First-in-human results of terbium-161[161Tb]Tb-PSMA-I&amp;T radioligand treatment in patients with metastatic castration-resistant prostate cancer (VIOLET) Presented at #ASCO25 

meetings.asco.org/abstracts-pres…

In this phase I/II trial, the novel radioligand therapy [¹⁶¹Tb]Tb-PSMA-I&amp;T
Shankar Siva (@_shankarsiva) 's Twitter Profile Photo

🄳 Today, we randomised the final patient on Trans Tasman Radiation Oncology Group 19.06 DECREASE trial! This trial randomised patients with prostate cancer who were becoming resistant to hormone therapy, without evidence of metastases on bone or CT scan, to Darolutamide +/- Stereotactic

🄳  Today, we randomised the final patient on <a href="/TROGfightcancer/">Trans Tasman Radiation Oncology Group</a>  19.06 DECREASE trial! This trial randomised patients with prostate cancer who were becoming resistant to hormone therapy, without evidence of metastases on bone or CT scan, to Darolutamide +/- Stereotactic
Michael Hofman (@drmhofman) 's Twitter Profile Photo

620 of 660 patients randomised in #PRIMARY2 šŸŽÆBringing PSMA PET from staging to DIAGNOSIS šŸThe finishing line approaches Thank-you⭐investigators James Buteau Louise Emmett Daniel Moon Declan Murphy + many more Supported by Peter Mac Cancer Centre @SVHSydney PCF Science ProsTIC

620 of 660 patients randomised  in #PRIMARY2 
šŸŽÆBringing PSMA PET from staging to DIAGNOSIS
šŸThe finishing line approaches

Thank-you⭐investigators <a href="/ButeauJames/">James Buteau</a>  <a href="/drlouiseemmett/">Louise Emmett</a> <a href="/DrDanielMoon/">Daniel Moon</a> <a href="/declangmurphy/">Declan Murphy</a> + many more

Supported by <a href="/PeterMacCC/">Peter Mac Cancer Centre</a> @SVHSydney <a href="/PCF_Science/">PCF Science</a> <a href="/pros_tic/">ProsTIC</a>
Michael Hofman (@drmhofman) 's Twitter Profile Photo

#VIOLET Study of Terbium-161 (161Tb) - first trial of Beta/Auger therapy. Recently presented #ASCO25. Now out in The Lancet Oncology : thelancet.com/journals/lanon… 🟣 30 patient trial in prostate cancer. No dose limiting toxicities at highest level of radioactivity (7.4 GBq) 🟣Very few

Advanced Prostate Cancer Consensus Conference (@apccc_lugano) 's Twitter Profile Photo

First-in-human results of terbium-161 [161Tb]Tb-PSMA-I&T dual beta–Auger radioligand therapy in patients with metastatic castration-resistant prostate cancer (VIOLET) thelancet.com/journals/lanon… The VIOLET phase 1/2 trial evaluated the safety of the novel radioligand therapy

First-in-human results of terbium-161 [161Tb]Tb-PSMA-I&amp;T dual beta–Auger radioligand therapy in patients with metastatic castration-resistant prostate cancer (VIOLET)

thelancet.com/journals/lanon…

The VIOLET phase 1/2 trial evaluated the safety of the novel radioligand therapy